Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry

Simple item page
dc.contributor.authorAsiimwe, Innocent G
dc.contributor.authorBlockman, Marc
dc.contributor.authorCavallari, Larisa H
dc.contributor.authorCohen, Karen
dc.contributor.authorCupido, Clint
dc.contributor.authorDandara, Collet
dc.contributor.authorDavis, Brittney H
dc.contributor.authorJacobson, Barry
dc.contributor.authorJohnson, Julie A
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorLimdi, Nita A
dc.contributor.authorMorgan, Jennie
dc.contributor.authorMouton, Johannes P
dc.contributor.authorMuyambo, Sarudzai
dc.contributor.authorNakagaayi, Doreen
dc.contributor.authorNdadza, Arinao
dc.contributor.authorOkello, Emmy
dc.contributor.authorPerera, Minoli A
dc.contributor.authorSchapkaitz, Elise
dc.contributor.authorSekaggya-Wiltshire, Christine
dc.contributor.authorSemakula, Jerome R
dc.contributor.authorTatz, Gayle
dc.contributor.authorWaitt, Catriona
dc.contributor.authorYang, Guang
dc.contributor.authorZhang, Eunice J
dc.contributor.authorJorgensen, Andrea L
dc.contributor.authorPirmohamed, Munir
dc.date.accessioned2024-10-22T09:14:15Z
dc.date.available2024-10-22T09:14:15Z
dc.date.issued2024-10-20
dc.description.abstractWarfarin dose requirements are highly variable because of clinical and genetic factors. Although genetic variants influencing warfarin dose have been identified in European and East Asian populations, more work is needed to identify African-specific genetic variants to help optimize warfarin dosing. We performed genome-wide association studies (GWASs) in 4 African cohorts from Uganda, South Africa, and Zimbabwe, totaling 989 warfarin-treated participants who reached stable dose and had international normalized ratios within therapeutic ranges. We also included 2 African American cohorts recruited by the International Warfarin Pharmacogenetics Consortium (n = 316) and the University of Alabama at Birmingham (n = 199). After the GWAS, we performed standard error-weighted meta-analyses and then conducted stepwise conditional analyses to account for known loci in chromosomes 10 and 16. The genome-wide significance threshold was set at P < 5 × 10-8. The meta-analysis, comprising 1504 participants, identified 242 significant SNPs across 3 genomic loci, with 99.6% of these located within known loci on chromosomes 10 (top SNP: rs58800757, P = 4.27 × 10-13) and 16 (top SNP: rs9925964, P = 9.97 × 10-16). Adjustment for the VKORC1 SNP -1639G>A revealed an additional locus on chromosome 2 (top SNPs rs116057875/rs115254730/rs115240773, P = 3.64 × 10-8), implicating the MALL gene, that could indirectly influence warfarin response through interactions with caveolin-1. In conclusion, we reaffirmed the importance of CYP2C9 and VKORC1 in influencing warfarin dose requirements, and identified a new locus (MALL), that still requires direct evidence of biological plausibility.ABSTRACTWarfarin dose requirements are highly variable because of clinical and genetic factors. Although genetic variants influencing warfarin dose have been identified in European and East Asian populations, more work is needed to identify African-specific genetic variants to help optimize warfarin dosing. We performed genome-wide association studies (GWASs) in 4 African cohorts from Uganda, South Africa, and Zimbabwe, totaling 989 warfarin-treated participants who reached stable dose and had international normalized ratios within therapeutic ranges. We also included 2 African American cohorts recruited by the International Warfarin Pharmacogenetics Consortium (n = 316) and the University of Alabama at Birmingham (n = 199). After the GWAS, we performed standard error-weighted meta-analyses and then conducted stepwise conditional analyses to account for known loci in chromosomes 10 and 16. The genome-wide significance threshold was set at P < 5 × 10-8. The meta-analysis, comprising 1504 participants, identified 242 significant SNPs across 3 genomic loci, with 99.6% of these located within known loci on chromosomes 10 (top SNP: rs58800757, P = 4.27 × 10-13) and 16 (top SNP: rs9925964, P = 9.97 × 10-16). Adjustment for the VKORC1 SNP -1639G>A revealed an additional locus on chromosome 2 (top SNPs rs116057875/rs115254730/rs115240773, P = 3.64 × 10-8), implicating the MALL gene, that could indirectly influence warfarin response through interactions with caveolin-1. In conclusion, we reaffirmed the importance of CYP2C9 and VKORC1 in influencing warfarin dose requirements, and identified a new locus (MALL), that still requires direct evidence of biological plausibility. MEDLINE - Academic
dc.identifier.citationAsiimwe, Innocent G., Marc Blockman, Larisa H. Cavallari, et al. 'Meta-Analysis of Genome-Wide Association Studies of Stable Warfarin Dose in Patients of African Ancestry', Blood Advances, vol. 8/no. 20, (2024), pp. 5248-5261.
dc.identifier.issnISSN 2473-9529, 2473-9537
dc.identifier.issnEISSN 2473-9537
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9669
dc.language.isoen
dc.publisherElsevier Inc
dc.titleMeta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
blooda_adv-2024-014227-main.pdf
Size:
3.75 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences